AZD1480: A phase I study of a novel JAK2 inhibitor in solid tumors

Oncologist

Volumn 18, Issue 7, 2013, Pages 819-820

  Plimack, Elizabeth R ^a   LoRusso, Patricia M ^b   McCoon, Patricia ^c   Tang, Weifeng ^c   Krebs, Annetta D ^c   Curt, Gregory ^c   Gail Eckhardt, S ^d  

^a FOX CHASE CANCER CENTER   (United States)

^b KARMANOS CANCER INSTITUTE   (United States)

^c ASTRAZENECA   (United Kingdom)

^d UNIVERSITY OF COLORADO CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 CHLORO N2 [1 (5 FLUORO 2 PYRIMIDINYL) ETHYL] N4 (5 METHYL 1H PYRAZOL 3 YL) 2, 4 PYRIMIDINEDIAMINE; 5 CHLORO N2 [1 (5 FLUORO 2 PYRIMIDINYL)ETHYL] N4 (5 METHYL 1H PYRAZOL 3 YL) 2,4 PYRIMIDINEDIAMINE; STAT3 PROTEIN; UNCLASSIFIED DRUG; JAK2 PROTEIN, HUMAN; JANUS KINASE 2; PYRAZOLE DERIVATIVE; PYRIMIDINE DERIVATIVE;

AMNESIA; ANXIETY DISORDER; ARTICLE; ATAXIA; BEHAVIOR CHANGE; CLINICAL ARTICLE; DIZZINESS; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; HALLUCINATION; HUMAN; MAXIMUM PLASMA CONCENTRATION; MONOTHERAPY; PHARMACODYNAMICS; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SOLID TUMOR; ADVERSE DRUG REACTION; ANTAGONISTS AND INHIBITORS; CLASSIFICATION; CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; FEMALE; GENETICS; MALE; NEOPLASMS; PATHOLOGY; SIGNAL TRANSDUCTION;

DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; HUMANS; JANUS KINASE 2; MALE; NEOPLASMS; PYRAZOLES; PYRIMIDINES; SIGNAL TRANSDUCTION;

EID: 84880691700     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2013-0198     Document Type: Article

References (9)

1. Levy DE, Inghirami G. Stat3: A multifaceted oncogene. Proc Natl Acad Sci USA 2006;103:10151-10152.
2. Dhir R, Ni Z, Lou W et al. Stat3 activation in prostatic carcinomas. Prostate 2002;51:241-246.
3. Grandis JR, Drenning SD, Zeng Q et al. Constitutive activation of Stat3 signaling abrogates apoptosis insquamouscell carcinogenesis in vivo. Proc Natl Acad Sci USA 2000;97:4227-4232.
4. Silver DL, Naora H, Liu J et al. Activated signal transducer and activator of transcription (STAT) 3: Localization in focal adhesions and function in ovarian cancer cell motility. Cancer Res 2004;64:3550-3558.
5. Grivennikov S, Karin E, Terzic J et al. Il-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. Cancer Cell 2009;15:103-113.
6. Inda MM, Bonavia R, Mukasa A et al. Tumorheterogeneity is an active process maintained by a mutant EGFR-induced cytokine circuit in glioblastoma. Genes Dev 2010;24:1731-1745.
7. Hedvat M, Huszar D, Herrmann A et al. The JAK2 inhibitor AZD1480 potently blocks Stat3 signaling and oncogenesis in solid tumors. Cancer Cell 2009; 16:487-497.
8. Skaper SD. The neurotrophin family of neurotrophic factors: An overview. Methods Mol Biol 2012;846:1-12.
9. Bergami M, Rimondini R, Santi S et al. Deletion of TrkB in adult progenitors alters newborn neuron integration into hippocampal circuits and increases anxiety-like behavior. Proc Natl Acad Sci USA 2008;105:15570-15575.